Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation- A Multicriteria Decision Analysis

Dec 1, 2017, 00:00
10.1016/j.jval.2017.06.006
https://www.valueinhealthjournal.com/article/S1098-3015(17)30309-1/fulltext
Title : Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation- A Multicriteria Decision Analysis
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30309-1&doi=10.1016/j.jval.2017.06.006
First page : 1394
Section Title : PREFERENCE-BASED ASSESSMENTS
Open access? : No
Section Order : 18

Background

Decision on the most appropriate oral anticoagulation therapy for stroke prevention in patients with nonvalvular atrial fibrillation is difficult because multiple treatment options are available, and these vary in their clinical effects and relevant nonclinical characteristics.

Objectives

To use a multicriteria decision analysis (MCDA) to compare the oral anticoagulants apixaban, dabigatran, edoxaban, rivaroxaban, and vitamin K antagonist (VKAs; specifically warfarin) in patients with nonvalvular atrial fibrillation.

Methods

We identified the evaluation criteria through a targeted literature review and clinical judgment. The final evaluation model included nine clinical events and four other criteria. We ranked possibly fatal clinical event criteria on the basis of the differences in risks of fatal events and the corresponding window of therapeutic opportunity, as observed in clinical trials. Clinical judgment was used to rank other criteria. Full criteria ranking was used to calculate centroid weights, which were combined with individual treatment performances to estimate the overall value score for each treatment.

Results

Using such an MCDA, dabigatran yielded the highest overall value, approximately 6% higher than that of the second-best treatment, apixaban. Dabigatran also had the highest first-rank probability (0.72) in the probabilistic sensitivity analysis. Rivaroxaban performed worse than the other non-VKA oral anticoagulants, but better than VKAs (with both having 0.00 first-rank probability). The results were insensitive to changes in model structure.

Conclusions

When all key oral anticoagulant value criteria and their relative importance are investigated in an MCDA, dabigatran appears to rank the highest and warfarin the lowest.

Categories :
Tags :
  • anticoagulation
  • atrial fibrillation
  • decision analysis
  • multicriteria decision analysis
Regions :
ViH Article Tags :